TScan Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from TScan Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, is 4.0 times its market value (net cash). Higher than almost all Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-27.0×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 62% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 0/3Sales grew in 2 of the last 3 years; profit grew in 0 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 24%
Sales fell 24% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-24% / +15%In 3 years sales changed by -24% while total assets changed by +15%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-18.9×Operating cash was negative last year, while some debt falls due within a year.
Lower than 54% of Healthcare companies in United States.
Cash Cushion Ratio
4.0× cashCash, after subtracting all debt, is 4.0 times its market value (net cash).
Higher than almost all Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
TScan Therapeutics, Inc. made a loss over the last year. TScan Therapeutics, Inc. owes $0.60 for every $1 it owns. TScan Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossTScan Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.21The share price is 0.21 times TScan Therapeutics, Inc.'s book value per share, lower than 98% of Healthcare companies in United States.
Market cap
$15 MThe total market value of all of TScan Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 84% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$69 MWhat TScan Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.02Net worth divided by the number of shares. The share price of $0.22 is 0.2 times this, which is the P/B above.
Return on equity (ROE)
-95.8%TScan Therapeutics, Inc. lost 95.8% of its shareholders' money over the last year, lower than 69% of Healthcare companies in United States.
Owes vs Owns
0.60×TScan Therapeutics, Inc. owes $0.60 for every $1 it owns (moderate), higher than 64% of Healthcare companies in United States.
Dividend yield
NoneTScan Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
+267%Revenue rose 267% in the year to Dec 2025, and shrank 9% a year on average over 3 years.
Profit growth
LossTScan Therapeutics, Inc. made a loss in each of the last two years.
Profit margin
-1256.8%TScan Therapeutics, Inc. lost $1257 for every $100 of revenue.
Interest cover
Not coveredTScan Therapeutics, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashTScan Therapeutics, Inc. held $58 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For TScan Therapeutics, Inc.: $15 M ÷ $69 M (30 Jun 2026) = 0.2.
What is TScan Therapeutics, Inc.'s return on equity?
TScan Therapeutics, Inc. lost 95.8% of its shareholders' money over the last year, lower than 69% of Healthcare companies in United States.
How much does TScan Therapeutics, Inc. owe compared with what it owns?
TScan Therapeutics, Inc. owes $0.60 for every $1 it owns (moderate), higher than 64% of Healthcare companies in United States.
Does TScan Therapeutics, Inc. pay a dividend?
No. TScan Therapeutics, Inc. does not currently pay a dividend.
Is TScan Therapeutics, Inc.'s revenue growing?
Revenue rose 267% in the year to Dec 2025, and shrank 9% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.